Supplements

Daridorexant 25 mg improves objective and subjective sleep metrics in insomnia patients over 3 months

In a meta-analysis of 6 RCTs with 2905 insomnia patients, daridorexant 25 mg showed sustained efficacy in objective sleep measures (LPS, WASO) at 3 months and in subjective total sleep time (sTST) at 3 months (SMD 0.25 [0.14, 0.36], P < 0.0001). The 25 mg dose was associated with an increased risk of adverse events of special interest (AESIs) compared to placebo (RR 4.00 [1.64, 9.76], P = 0.002).

Last updated: Jul 25, 2026•0 RCTs•1 Meta-analyses•📖 Read as article →

Evidence Score

Evidence Score49/100
Human RCT☆☆☆☆☆
Meta-analysis★★★☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. The "efficacy window" phenomenon of daridorexant in insomnia treatment: a dose-dependent time-course meta-analysis.

observational

Wang X, Wang Y, Wang M, Zheng Q, Li M, Zheng Y, Gao Y, Song W, Bo J, Guo H, Wang Z, Luo S · Frontiers in pharmacology (2026)

Participants: N/A
Duration: 3 months
Intervention: Daridorexant at doses of 10 mg, 25 mg, and 50 mg compared to placebo
Outcome: Objective: latency to persistent sleep (LPS), wake time after sleep onset (WASO); Subjective: subjective latency to sleep onset (sLSO), subjective total sleep time (sTST), Visual analog scale (VAS), IDSIQ sleepiness domain score, insomnia severity index (ISI); Safety: TEAEs, SAEs, AESIs
Effect Size: SMD 0.25 [0.14, 0.36] for sTST at 3 months with 25 mg
Population: 2905 patients with insomnia from 6 randomized controlled trials

Result:

PubMed: 42453571DOI: 10.3389/fphar.2026.1847130

Mechanism Graph

Daridorexant binds to orexin receptors
↓
Blocks orexin signaling
↓
Reduces wakefulness
↓
Improves sleep maintenance and onset

Limitations

  • ⚠Only 5 articles and 6 RCTs were included, limiting generalizability
  • ⚠Heterogeneity was observed in some subjective outcomes (I2 = 52% for sTST)
  • ⚠The increased risk of AESIs with 25 mg requires further investigation

Frequently Asked Questions

What is the efficacy window for daridorexant?▼

The efficacy is dose-dependent, with 25 mg and 50 mg showing short-term (1 month) benefits, and 25 mg sustaining efficacy in objective metrics up to 3 months.

Is daridorexant 25 mg safe for long-term use?▼

Overall safety is comparable to placebo, but the 25 mg dose significantly increases the risk of adverse events of special interest (AESIs) such as potential safety signals.

How does daridorexant compare to placebo for subjective sleep?▼

At 1 month, daridorexant outperformed placebo on most subjective indicators; at 3 months, only the 25 mg dose remained effective for subjective total sleep time.

What objective sleep measures improved with daridorexant?▼

Latency to persistent sleep (LPS) and wake time after sleep onset (WASO) improved with daridorexant compared to placebo at 1-2 days, 1 month, and for 25 mg at 3 months.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Wang X, Wang Y, Wang M, Zheng Q, Li M, Zheng Y, Gao Y, Song W, Bo J, Guo H, Wang Z, Luo S. "The "efficacy window" phenomenon of daridorexant in insomnia treatment: a dose-dependent time-course meta-analysis.." Frontiers in pharmacology, 2026. PMID: 42453571 DOI: 10.3389/fphar.2026.1847130
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.